Antifungal agents for onychomycoses.;Antifú ngicos disponiblesparaeltratamientodelasmicosisungueales

Revista Iberoamericana de Micologia

Volumn 27, Issue 2, 2010, Pages 49-56

  Carrillo Muñoz, Alfonso Javier ^a   Tur Tur, Cristina ^b   Hernández Molina, Juan Manuel ^c   Santos, Patricia ^d   Cárdenes, Delia ^a   Giusiano, Gustavo ^e  

^a Associacio Catalana d'Intelligencia Artificial   (Spain)

^b Centre d'Atenció Prima ria CAP Manso   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^e UNIVERSIDAD NACIONAL DEL NORDESTE   (Argentina)

Author keywords

Antifungal drugs; Dermatophytes; Onychomycosis; Yeasts

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; BIFONAZOLE; CICLOPIROXOLAMINE; GRISEOFULVIN; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; PYRROLE DERIVATIVE; SERTACONAZOLE; TERBINAFINE; TIOCONAZOLE;

COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG INDICATION; ONYCHOMYCOSIS; SHORT SURVEY; TREATMENT RESPONSE; DRUG COMBINATION; HUMAN; ORAL DRUG ADMINISTRATION; REVIEW; TOPICAL DRUG ADMINISTRATION;

ARTHRODERMATACEAE;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; ONYCHOMYCOSIS;

EID: 77952885028     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.riam.2010.01.007     Document Type: Short Survey

References (109)

1. Aguilar C., Pujol I., Guarro J. In vitro antifungal susceptibilities of Scopulariopsis isolates. Antimicrob Agents Chemother 1999, 43:1520-1522.
2. Armijo M, editor. Dermatosis por hongos. Madrid: Editorial Médica Internacional SA; 1989.
3. Bada Ainsa J.L. Tratamiento farmacológico de las micosis. Micosis que afectan piel y mucosas 1989, 137-163. Doyma, Barcelona. J.M. Torres-Rodríguez (Ed.).
4. Baran R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br J Dermatol 2001, 145:15-19.
5. Baran R., Gupta A.K., Piérard G.E. Pharmacotherapy of onychomycosis. Expert Opin Pharmacother 2005, 6:609-624.
6. Baran R., Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: An overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005, 19:21-29.
7. Baran R., Hay R.J., Garduno J.I. Review of antifungal therapy and the severity index for assessing onychomycosis: Part I. J Dermatolog Treat 2008, 19:72-81.
8. Baran R., Richert B. The management of onychomycosis. Ann Dermatol Venereol 2003, 130:1260-1271.
9. Barak O., Loo D.S. AN-2690, a novel antifungal for the topical treatment of onychomycosis. Curr Opin Investig Drugs 2007, 8:662-668.
10. Bellmann R. Clinical pharmacokinetics of systemically administered antimycotics. Curr Clin Pharmacol 2007, 2:37-58.
11. Bentley-Phillips B. The treatment of onychomycosis with miconazole tincture. S Afr Med J 1982, 62:57-58.
12. Bonifaz A., Ibarra G. Onychomycosis in children: Treatment with bifonazole-urea. Pediatr Dermatol 2000, 17:310-314.
13. Bonifaz A., Saúl A. Comparative study between terbinafine 1% emulsion-gel versus ketoconazole 2% cream in tinea cruris and tinea corporis. Eur J Dermatol 2000, 10:107-109.
14. Borgers M. Ultraestructural correlates of antimycotic treatment. Current topics in medical Mycology 1989, 1-39. Springuer Verlag, New York. M.R. McGinnis (Ed.).
15. Braga P.C., Piatti G., Conti E., Vignali F. Effects of subinhibitory concentrations of ciclopirox in the adherence of Candida albicans to human bucal and vaginal cells. Arzn Forch 1992, 42:1368-1371.
16. Campbell A.W., Anyanwu E.C., Morad M. Evaluation of the drug treatment and persistence of onychomycosis. Scientific World Journal 2004, 4:760-777.
17. Carrillo-Muñoz A.J. Etiología de las dermatomicosis ungueales. Actualidad Dermatológica 2004, 43:564-574.
18. Carrillo-Muñoz A.J., Brió S., Quindós G. Una nueva generación de fármacos antifúngicos. Rev Iberoam Micol 2001, 18:4-7.
19. Carrillo-Muñoz A.J., Cárdenes D.C., Carrillo-Orive B., Rodríguez V., Del Valle O., Casals J., et al. Actividad antifúngica de voriconazol frente a hongos dermatofitos y Scopulariopsis brevicaulis determinada por el método de difusión en agar NeoSensitabs. Rev Iberoam Micol 2005, 22:110-113.
20. Carrillo-Muñoz A.J., Fernández-Torres B., Cárdenes D.C., Guarro J. In vitro activity of sertaconazole against dermatophyte moulds isolates with reduced fluconazole susceptibility. Chemother 2003, 49:248-251.
21. Carrillo-Muñoz A.J., Giusiano G., Cárdenes D., Hernández-Molina J.M., Eraso E., Quindós G., et al. Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis. Int J Antimicrob Agents 2008, 31:540-543.
22. Carrillo-Muñoz A.J., Giusiano G., Ezkurra P.A., Quindós G. Mecanismos de acción de antifúngicos en levaduras. Rev Esp Quimioter 2006, 19:130-139.
23. Carrillo-Muñoz A.J., Giusiano G., Ezkurra P.A., Quindós G. Sertaconazole: Updated review of a topical antifungal agent. Expert Rev Anti Infect Ther 2005, 3:333-342.
24. Carrillo-Muñoz A.J., Giusiano G., Guarro J., Quindós G., Guardia C., Del Valle O., et al. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis. Int J Antimicrob Agents 2007, 30:157-161.
25. Carrillo-Muñoz A.J., Pemán J., Gobernado M. Nuevos antifúngicos. Rev Esp Quimioter 1999, 12:181-204.
26. Carrillo-Muñoz A.J., Quindós G., López-Ribot J.L. Current developments in antifungal agents: Present and future. Curr Med Chem Anti-Infect Agents 2004, 3:297-323.
27. Carrillo-Muñoz A.J., Quindós G., Tur C., Ruesga M., Alonso R., del Valle O., et al. Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole. Chemother 2000, 46:235-244.
28. Carrillo-Muñoz A.J., Tur C., Estivill D., Torres J.M., Estivill D. In vitro antifungal activity of sertaconazole and bifonazole against dermatophytes. J Mycol Med 1995, 5:235-238.
29. Chambers W.M., Millar A., Jain S., Burroughs A.K. Terbinafine-induced hepatic dysfunction. Eur J Gastroenterol Hepatol 2001, 13:1115-1118.
30. Chang C.H., Young-Xu Y., Kurth T., Orav J.E., Chan A.K. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: A meta-analysis. Am J Med 2007, 120:791-798.
31. Chen S.C., Sorrell T.C. Antifungal agents. Med J Aust 2007, 187:404-409.
32. Cuenca-Estrella M., Gómez-López A., Buitrago M.J., Mellado E., García-Effron G., Rodríguez-Tudela J.L. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. Antimicrob Agents Chemother 2006, 50:2248-2250.
33. Del Palacio A., Garau M., Cuétara M.S. Tratamiento actual de las dermatofitosis. Rev Iberoam Micol 2002, 19:69-71.
34. Dupont B. Use of topical antifungal agents. Therap 2006, 61:251-254.
35. Elewski B.E. Onychomycosis. Treatment, quality of life, and economic issues. Am J Clin Dermatol 2000, 1:19-26.
36. Espinel-Ingroff A. In vitro antifungal susceptibility methods and clinical applications of antifungal resistance. J Mycol 2000, 38:293-304.
37. Evans E.G. Drug synergies and the potential for combination therapy in onychomycosis. Br J Dermatol 2003, 149:11-13.
38. Faergemann J., Zehender H., Denouël J., Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250mg terbinafine orally once per day for four weeks. Acta Derm Venereol 1993, 73:305-309.
39. Fernández-Torres B., Carrillo-Muñoz A.J., Martín E., Del Palacio A., Moore M.B., Valverde A., et al. In vitro of ten antifungal drugs against 508 strains of dermatophytes. Antimicrob Agents Chemother 2001, 45:2524-2528.
40. Finch J.J., Warshaw E.M. Toenail onychomycosis: Current and future treatment options. Dermatol Ther 2007, 20:31-46.
41. Flagothier C., Piérard-Franchimont C., Piérard G.E. New insights into the effect of amorolfine nail lacquer. Mycoses 2005, 48:91-94.
42. Fromtling R.A. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev 1988, 1:187-217.
43. García-Martos P., Domínguez I., Marín P., Linares M., Mira J., Calap J. Onicomicosis causadas por hongos no dermatofitos en Cádiz. Enferm Infecc Microbiol Clin 2000, 18:319-324.
44. Ghannoum M., Isham N., Sheehan D. Voriconazole susceptibilities of dermatophyte isolates obtained from a worldwide tinea capitis clinical trial. J Clin Microbiol 2006, 44:2579-2580.
45. Ghannoum M.A., Long L., Pfister W.R. Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model. Mycoses 2009, 52:35-43.
46. Grover C., Bansal S., Nanda S., Reddy B.S., Kumar V. Combination of surgical avulsion and topical therapy for single nail onychomycosis: A randomized controlled trial. Br J Dermatol 2007, 157:364-368.
47. Gupta A.K. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. J Am Acad Dermatol 2000, 43:S81-S95.
48. Gupta A.K. Ciclopirox nail lacquer topical solution 8%. Skin Therapy Lett 2000, 6:1-5.
49. Gupta A.K. Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis. J Am Podiatr Med Assoc 2002, 92:272-286.
50. Gupta A.K. Ciclopirox nail lacquer: A brush with onychomycosis. Cutis 2001, 68:13-16.
51. Gupta A.K., Baran R. Ciclopirox nail lacquer solution 8% in the 21st century. J Am Acad Dermatol 2000, 43:S96-S102.
52. Gupta A.K., Carney P.S., Jegasothy S.M., Turner J.E., Werschler W.P., Epstein B. Onychomycosis: Management and treatment. Cutis 2004, 74:16-25.
53. Gupta A.K., Cooper E.A. Update in antifungal therapy of dermatophytosis. Mycopathol 2008, 166:353-367.
54. Gupta A.K., Lynch L.E. Management of onychomycosis: Examining the role of monotherapy and dual, triple, or quadruple therapies. Cutis 2004, 74:5-9.
55. Gupta A.K., Cooper E.A., Ryder J.E., Nicol K.A., Chow M., Chaudhry M.M. Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol 2004, 5:225-237.
56. Gupta A.K., Lynde C.W., Barber K. Pharmacoeconomic assessment of ciclopirox topical solution, 8%, oral terbinafine, and oral itraconazole for onychomycosis. J Cutan Med Surg 2006, 10:S54-S62.
57. Gupta A.K., Malkin K.F. Ciclopirox nail lacquer and podiatric practice. J Am Podiatr Med Assoc 2000, 90:502-507.
58. Gupta A.K., Ryder J.E. How to improve cure rates for the management of onychomycosis. Dermatol Clin 2003, 21:499-505.
59. Gupta A.K., Ryder J.E., Baran R. The use of topical therapies to treat onychomycosis. Dermatol Clin 2003, 21:481-489.
60. Gupta A.K., Ryder J.E., Lynch L.E., Tavakkol A. The use of terbinafine in the treatment of onychomycosis in adults and special populations: A review of the evidence. J Drugs Dermatol 2005, 4:302-308.
61. Gupta A.K., Ryder J.E., Skinner A.R. Treatment of onychomycosis: Pros and cons of antifungal agents. J Cutan Med Surg 2004, 8:25-30.
62. Hay R.J. The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol 2001, 145:3-8.
63. Jaiswal A., Sharma R.P., Garg A.P. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol 2007, 73:393-396.
64. Jansen R., Redekop W.K., Rutten F.F. Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: An análisis of based on results from the L.I.ON. Study. Lamisil versus itraconazole in onychomycosis. Pharmacoecon 2001, 19:401-410.
65. Johnson E.M., Szekely A., Warnock D.W. In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mould pathogens. Antimicrob Agents Chemother 1999, 43:1260-3126.
66. Katz H.I. How should managed care treat onychomycosis?. Am J Manag Care 1998, 4:1471-1479.
67. Joish V.N., Armstrong E.P. Which antifungal agent for onychomycosis? A pharmacoeconomic analysis. Pharmacoecon 2001, 19:983-1002.
68. Kaur R., Kashyap B., Bhalla P. Onychomycosis: Epidemiology, diagnosis and management. Indian J Med Microbiol 2008, 26:108-116.
69. Knasmüller S., Parzefall W., Helma C., Kassie F., Ecker S., Schulte-Hermann R. Toxic effects of griseofulvin: Disease models, mechanisms, and risk assessment. Crit Rev Toxicol 1997, 27:495-537.
70. Korting H.C., Grundmann-Kollmann M. The hydroxypyridones: A class of antimycotics of its own. Mycoses 1997, 40:243-247.
71. Korting H.C., Ollert M., Abeck D. Results of german mulcicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. Antimicrob Agents Chemother 1995, 39:1206-1208. German collaborative dermatophyte drug susceptibility study group.
72. Lambert J. Pharmacoeconomic issues in onychomycosis. Br J Dermatol 2003, 149:19-22.
73. Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br J Dermatol 2001, 145:21-26.
74. Lecha M., Effendy I., Feuilhade de Chauvin M., Di Chiacchio N., Baran R. Taskforce on onychomycosis education. Treatment options--development of consensus guidelines. J Eur Acad Dermatol Venereol 2005, 19:25-33.
75. Lecha-Carralero V., Martínez-Tomás C. Experience in the treatment of skin mycoses with ciclopiroxolamine. Med Cutanea Ibero Lat Am 1989, 17:35-38.
76. Lipp H.P. Antifungal agents-clinical pharmacokinetics and drug interactions. Mycoses 2008, 51:7-18.
77. Loo D.S. Onychomycosis in the elderly: Drug treatment options. Drugs Aging 2007, 24:293-302.
78. Llambrich A., Lecha M. Tratamiento actual de las oniconicosis. Rev Iberoam Micol 2002, 19:127-129.
79. Mishra M., Panda P., Tripathy S., Sengupta S., Mishra K. An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol 2005, 71:262-266.
80. Murdan S. Enhancing the nail permeability of topically applied drugs. Expert Opin Drug Deliv 2008, 5:1267-1282.
81. Okamoto J., Fukunami M., Kioka H. Frequent premature ventricular contractions induced by itraconazole. Circ J 2007, 71:1323-1325.
82. Olafsson J.H., Sigurgeirsson B., Baran R. Combination therapy for onychomycosis. Dermatol 2003, 149:15-18.
83. Oliveri S., Cammarata E., Cappello G., Di Prima T., Fallica L., Panizza E. Ciclopiroxolamine: Clinical and microbiological considerations. Preliminary data. Chimioterapia 1986, 5:23-25.
84. Perea S., Fothergill A.W., Sutton D.A., Rinaldi M.G. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. J Clin Microbiol 2001, 39:385-388.
85. Ritschel W.A., Hussain A.S. In vitro skin penetration of griseofulvin in rat and human skin from an ointment dosage form. Arzneim Fosch 1988, 38:1630-1632.
86. Ryder N.S. Activity of terbinafine against serious fungal pathogens. Mycoses 1999, 42:115-119.
87. Sánchez-Schmidt J.M., Giménez-Jovani S., Peyrí-Rey J. Study on patient satisfaction with the treatment of mycosis on the extremities with terbinafine (SETTA). Act Dermosifiliogr 2005, 96:2852-2890.
88. Scheinfeld N. A review of the new antifungals: Posaconazole, micafungin, and anidulafungin. J Drugs Dermatol 2007, 6:1249-1251.
89. Scher R.K., Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Dermatol 2003, 149:5-9.
90. Seebacher C. Action mechanisms of modern antifungal agents and resulting problems in the management of onychomycosis. Mycoses 2003, 46:506-510.
91. Serrano-Martino M.C., Chávez-Caballero M., Valverde-Conde A., Claro R.M., Pemán J., Martín-Mazuelos E. In vitro activity of voriconazole and three other antifungal agents against dermatophytes. Enferm Infecc Microbiol Clin 2003, 21:484-487.
92. Shemer A., Bergman R., Cohen A., Friedman-Birnbaum R. Treatment of onychomycosis using 40% urea with 1% bifonazole. Harefuah 1992, 122:159-160.
93. Sidou F., Soto P. A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers. Int J Tissue React 2004, 26:17-24.
94. Sobue S., Sekiguchi K., Nabeshima T. Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in Guinea pigs and binding to human stratum corneum. Antimicrob Agents Chemother 2004, 48:216-223.
95. Stier D.M., Henke C., Schein J., Doyle J., Schonfeld W.H., Broering J. Cost of treatment for onychomycosis. Data from a 9-month observational study. Pharmacoecon 2001, 19:267-279.
96. Stubb S., Heikkilä H., Reitamo S., Förström L. Contact allergy to tioconazole. Contact allergy to tioconazole. Contact Dermatitis 1992, 26:155-158.
97. Susilo R., Korting H.C., Greb W., Strauss U.P. Nail penetration of sertaconazole with a sertaconazole-containing nail patch formulation. Am J Clin Dermatol 2006, 7:259-262.
98. Svejgaard E.L., Nilsson J. Onychomycosis in Denmark: Prevalence of fungal nail infection in general practice. Mycoses 2004, 47:131-135.
99. 't Jong G.W., Stricker B.H., Sturkenboom M.C. Marketing in the lay media and prescriptions of terbinafine in primary care: Dutch cohort study. BMJ 2004, 328:931.
100. Tatsumi Y., Yokoo M., Senda H., Kakehi K. Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine. Antimicrob Agents Chemother 2002, 46:3797-3801.
101. Torres J.M. Ciclopiroxolamina. Un nuevo antifúngico tópico, uso terapéutico. Drugs Today 1989, 25:1-17.
102. Trey S.M., Wicks D.A., Mididoddi P.K., Repka M.A. Delivery of itraconazole from extruded HPC films. Drug Dev Ind Pharm 2007, 33:727-735.
103. Warshaw E.M., Bowman T., Bodman M.A., Kim J.J., Silva S., Mathias S.D. Satisfaction with onychomycosis treatment. Pulse versus continuous dosing. J Am Podiatr Med Assoc 2003, 93:373-379.
104. Tsuboi R., Unno K., Komatsuzaki H., Ogawa H., Kasai T., Oka K., et al. Topical treatment of onychomycosis by occlusive dressing using bifonazole cream containing 40% urea. Nipp Ishinkin Gakkai Zasshi 1998, 39:11-16.
105. Warshaw E.M., St Clair K.R. Prevention of onychomycosis reinfection for patients with complete cure of all 10 toenails: Results of a double-blind, placebo-controlled, pilot study of prophylactic miconazole powder 2%. J Am Acad Dermatol 2005, 53:717-720.
106. Wilcock M., Hartley J., Gould D. Inappropriate use of oral terbinafine in family practice. Pharm World Sci 2003, 25:25-26.
107. Wildfeuer A., Seidl H.P., Paule I., Haberreiter A. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 1998, 41:309-319.
108. Yang D., Michel L., Chaumont J.P., Millet-Clerc J. Use of caryophyllene oxide as an antifungal agent in an in vitro experimental model of onychomycosis. Mycopathol 1999, 148:79-82.
109. Zonios D.I., Bennett J.E. Update on azole antifungals. Semin Respir Crit Care Med 2008, 29:198-210.